Short Interest Update on BioDelivery Sciences International (BDSI)

BioDelivery Sciences International (BDSI) : Traders are negative on BioDelivery Sciences International (BDSI), as it has 16.3% of short positions outstanding compared to its float. The total shorts have reduced by -920,230 shares, which is a -10.3% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,8,952,702 to 8,032,472 shares. While the daily trading volume of the stock is 707,086, there are 11 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

BioDelivery Sciences International (NASDAQ:BDSI): The stock opened at $2.83 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.86 for the day. The stock traded down to $2.51 during the day, due to lack of any buying support eventually closed down at $2.51 with a loss of -11.62% for the day. The stock had closed at $2.84 on the previous day. The total traded volume was 1,083,430 shares.


In a related news, Stone William B, director of Biodelivery Sciences International Inc, unloaded 16,000 shares at an average price of $2.57 on August 11, 2016. The total amount of the transaction was worth $41,120, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.